Kazia Therapeutics Says Nasdaq Determined That Company Is Eligible For Additional 180 Calendar Day Period, Or Until November 18, 2024 To Regain Compliance
Portfolio Pulse from Benzinga Newsdesk
Kazia Therapeutics has been granted an additional 180 days by Nasdaq to regain compliance with the Minimum Bid Price Requirement. The company has until November 18, 2024, to ensure its stock price meets the $1.00 per share minimum for 10 consecutive business days.
May 23, 2024 | 11:14 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Kazia Therapeutics has been granted an additional 180 days by Nasdaq to regain compliance with the Minimum Bid Price Requirement. The company has until November 18, 2024, to ensure its stock price meets the $1.00 per share minimum for 10 consecutive business days.
The extension provides Kazia Therapeutics with more time to meet Nasdaq's compliance requirements, which could stabilize investor sentiment in the short term. However, the company still needs to achieve the $1.00 per share minimum, leaving uncertainty about its ability to comply.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100